Frontage Holdings Corporation (HKG:1521)

Market Cap	2.11B -1.7%
Revenue (ttm)	2.00B +0.7%
Net Income	52.87M +758.8%
EPS	0.03 +745.9%
Shares Out	2.03B
PE Ratio	40.50
Forward PE	15.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,000
Average Volume	69,200
Open	1.050
Previous Close	1.040
Day's Range	1.050 - 1.050
52-Week Range	0.900 - 1.870
Beta	0.31
RSI	44.79
Earnings Date	Mar 30, 2026

About Frontage Holdings

Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 1,523
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1521

Financial Performance

In 2025, Frontage Holdings's revenue was $256.69 million, an increase of 0.70% compared to the previous year's $254.91 million. Earnings were $6.79 million, an increase of 758.79%.

Financial numbers in USD